Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT00003006
Official study title

Detection of Early Metastases in Patients With Stage I Non-small Cell Lung Cancer

Study summary

RATIONALE: Detecting very early metastases in bone marrow and/or lymph nodes may help doctors plan better treatment for non-small cell lung cancer. PURPOSE: Clinical trial to detect the presence of metastatic cancer in patients with stage I non-small cell lung cancer that has not been previously treated.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedreverse transcriptase-polymerase chain reaction and immunohistochemistry staining method

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 29, 2016 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?10 U.S. locations

Locations may change over time.

Who runs it?Alliance for Clinical Trials in Oncology

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Alliance for Clinical Trials in Oncology
Interventions being studied
Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Early-stage or resectable→Metastatic or stage IV→
Study topics
After prior treatment→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Clinical stage I proven or suspected new non-small cell lung carcinoma T1 or T2 primary N1 or N2 lymph nodes \<1cm on CT or negative mediastinoscopy
  • ≥ 5 years since prior chemo or XRT; no prior mediastinal or chest XRT.
  • ≥ 18 years of age
  • No history of previous lung cancer or concomitant malignancy

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Holden Comprehensive Cancer Center at The University of IowaIowa City, Iowa
  • Marlene & Stewart Greenebaum Cancer Center, University of MarylandBaltimore, Maryland
  • University of Minnesota Cancer CenterMinneapolis, Minnesota
  • University of Minnesota Medical SchoolMinneapolis, Minnesota
  • Ellis Fischel Cancer Center - ColumbiaColumbia, Missouri
  • Barnes-Jewish HospitalSt Louis, Missouri
  • Memorial Sloan-Kettering Cancer CenterNew York, New York
  • State University of New York - Upstate Medical UniversitySyracuse, New York
  • Lineberger Comprehensive Cancer Center, UNCChapel Hill, North Carolina
  • Duke Comprehensive Cancer CenterDurham, North Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 29, 2016. Always confirm current availability with the study team.

View original record ↗